BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 15160319)

  • 1. Zoledronate in a patient with pamidronate refractory hypercalcemia syndrome.
    Wenzel C; Bartsch R; Hussian D; Pluschnig U; Locker GJ; Sevelda U; Zielinski CC; Steger GG
    Support Care Cancer; 2004 Sep; 12(9):678-81. PubMed ID: 15160319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zoledronic acid: a new parenteral bisphosphonate.
    Li EC; Davis LE
    Clin Ther; 2003 Nov; 25(11):2669-708. PubMed ID: 14693298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy.
    Major P
    Oncologist; 2002; 7(6):481-91. PubMed ID: 12490736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Tumor-induced hypercalcemia. Review of bisphosphonate treatment].
    Lortholary A
    Rev Med Interne; 2001 Jul; 22(7):648-52. PubMed ID: 11508158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A dose-finding study of zoledronate in hypercalcemic cancer patients.
    Body JJ; Lortholary A; Romieu G; Vigneron AM; Ford J
    J Bone Miner Res; 1999 Sep; 14(9):1557-61. PubMed ID: 10469284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of hypercalcemia of malignancy with bisphosphonates.
    Berenson JR
    Semin Oncol; 2002 Dec; 29(6 Suppl 21):12-8. PubMed ID: 12584690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical research update: zoledronate.
    Body JJ
    Cancer; 1997 Oct; 80(8 Suppl):1699-701. PubMed ID: 9362440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case of resistant hypercalcemia of malignancy with a proposed treatment algorithm.
    McMahan J; Linneman T
    Ann Pharmacother; 2009 Sep; 43(9):1532-8. PubMed ID: 19622757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zoledronic acid.
    Cheer SM; Noble S
    Drugs; 2001; 61(6):799-805; discussion 806. PubMed ID: 11398911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter and open label clinical trial of zoledronic acid 4 mg in patients with hypercalcemia of malignancy.
    Kawada K; Minami H; Okabe K; Watanabe T; Inoue K; Sawamura M; Yagi Y; Sasaki T; Takashima S
    Jpn J Clin Oncol; 2005 Jan; 35(1):28-33. PubMed ID: 15681601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cisplatin as an active treatment in zoledronate-refractory hypercalcemia.
    Lin PH; Chiu CF; Lu YS
    Ann Oncol; 2011 May; 22(5):1244-1246. PubMed ID: 21460375
    [No Abstract]   [Full Text] [Related]  

  • 12. The use of zoledronic acid in the management of metastatic bone disease and hypercalcaemia.
    Neville-Webbe Hl; Coleman RE
    Palliat Med; 2003 Sep; 17(6):539-53. PubMed ID: 14526888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bisphosphonates for metastatic bone pain.
    Body JJ
    Support Care Cancer; 1999 Jan; 7(1):1-3. PubMed ID: 9926966
    [No Abstract]   [Full Text] [Related]  

  • 14. Bisphosphonates and metastatic breast carcinoma.
    Lipton A
    Cancer; 2003 Feb; 97(3 Suppl):848-53. PubMed ID: 12548585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials.
    Major P; Lortholary A; Hon J; Abdi E; Mills G; Menssen HD; Yunus F; Bell R; Body J; Quebe-Fehling E; Seaman J
    J Clin Oncol; 2001 Jan; 19(2):558-67. PubMed ID: 11208851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metastatic bone disease and tumour-induced hypercalcaemia: the role of bisphosphonates.
    Heatley S
    Int J Palliat Nurs; 2001 Jun; 7(6):301-2, 304-7. PubMed ID: 12066026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current and future directions in medical therapy: hypercalcemia.
    Body JJ
    Cancer; 2000 Jun; 88(12 Suppl):3054-8. PubMed ID: 10898351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bisphosphonates: biological response modifiers in breast cancer.
    Paterson AH
    Clin Breast Cancer; 2002 Aug; 3(3):206-16; discussion 217-8. PubMed ID: 12196279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypercalcemia of malignancy.
    Body JJ
    Semin Nephrol; 2004 Jan; 24(1):48-54. PubMed ID: 14730509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zoledronic acid in the treatment of hypercalcemia of malignancy: results of the international clinical development program.
    Major PP; Coleman RE
    Semin Oncol; 2001 Apr; 28(2 Suppl 6):17-24. PubMed ID: 11346861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.